Shares of ADMA Biologics (NASDAQ: ADMA) surged 5.06% higher on Wednesday, as investors eagerly anticipate the company's third-quarter earnings report scheduled for release after the market close. The biopharmaceutical company, which develops and commercializes plasma-derived products for the prevention and treatment of infectious diseases, has captured market attention with expectations of positive financial results.

Wall Street analysts are projecting ADMA Biologics to report earnings of $0.15 per share for the quarter, signaling potential profitability and continued growth for the company. This optimistic outlook has fueled investor enthusiasm, driving the stock's significant intraday gain.

The pre-earnings rally suggests that market participants are betting on ADMA Biologics to meet or exceed these earnings expectations. Investors will be closely watching key metrics such as revenue growth, product sales, and any updates on the company's pipeline and commercialization efforts when the report is released later today.